Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
This randomized, open-label, active-controlled, dose-finding phase IIb study evaluated the efficacy and safety of trabedersen (AP 12009) administered intratumorally by convection-enhanced delivery compared with standard chemotherapy in patients with recurrent/refractory high-grade glioma. One hundred and forty-five patients with central reference histopathology of recurrent/refractory glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) were randomly assigned to receive trabedersen at doses of 10 or 80 µM or standard chemotherapy (temozolomide or procarbazine/lomustine/vincristine). Primary endpoint was 6-month tumor control rate, and secondary endpoints included response at further timepoints, survival, and safety. Six-month tumor control rates were not significantly different in the entire study population (AA and GBM). Prespecified AA subgroup analysis showed a significant benefit regarding the 14-month tumor control rate for 10 µM trabedersen vs chemotherapy (p= .0032). The 2-year survival rate had a trend for superiority for 10 µM trabedersen vs chemotherapy (p = .10). Median survival for 10 µM trabedersen was 39.1 months compared with 35.2 months for 80 µM trabedersen and 21.7 months for chemotherapy (not significant). In GBM patients, response and survival results were comparable among the 3 arms. Exploratory analysis on GBM patients aged ≤55 years with Karnofsky performance status >80% at baseline indicated a 3-fold survival at 2 and 3 years for 10 µM trabedersen vs chemotherapy. The frequency of patients with related or possibly drug-related adverse events was higher with standard chemotherapy (64%) than with 80 µM trabedersen (43%) and 10 µM trabedersen (27%). Superior efficacy and safety for 10 µM trabedersen over 80 µM trabedersen and chemotherapy and positive risk-benefit assessment suggest it as the optimal dose for further clinical development in high-grade glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, phase 1 clinical studies with trabedersen (AP12009), Lucanix (belagenpumatucel‐L), or with ASOs against TGF‐β2 mRNA, showed better survival in glioblastoma, melanoma, pancreatic cancer or colorectal cancer patients [173, 174].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [174]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409 · cited 1×
“Tumor assessments were done via central, blinded MRI readings of 2 independent radiologists and 1 adjudicator using the classical Macdonald criteria.(17) The tumor control rate was defined as the percentage of patients with complete response (CR) + partial response (PR) + stable disease (SD).”
MethodDAOUD, G. (1965) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1965.02090030355030 · Cited by 1,171
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
Lamborn, K. R., Chang, S. M., & Prados, M. D. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000620 · Cited by 546
Laske, D. W., Youle, R. J., & Oldfield, E. H. (1997) · Nature Medicine · doi:10.1038/nm1297-1362 · Cited by 525
Taal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E., Swaak‐Kragten, A. T., Sillevis Smitt, P. A. E., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465
Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I., & Fontana, A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3222 · Cited by 386
DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS
Brooks, W. H., Netsky, M. G., Normansell, D. E., & Horwitz, D. A. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.6.1631 · Cited by 368
Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
Chang, S. M. (2005) · JAMA · doi:10.1001/jama.293.5.557 · Cited by 362
Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1117 · Cited by 325
Endpoints for Assessing Drug Activity in Clinical Trials
Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s2-19 · Cited by 286
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
Hoos, A., Parmiani, G., Hege, K., Sznol, M., Loibner, H., Eggermont, A., Urba, W., Blumenstein, B., Sacks, N., Keilholz, U., et al. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211341.88835.ae · Cited by 270
PRIMARY BRAIN TUMORS IN ADULTS
(1994) · Continuum · doi:10.1212/00132979-199401020-00005 · Cited by 236
Kjellman, C., Olofsson, S. P., Hansson, O., Von Schantz, T., Lindvall, M., Nilsson, I., Salford, L. G., Sjögren, H.-O., & Widegren, B. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000520)89:3<251::aid-ijc7>3.0.co;2-5 · Cited by 224
Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F., Jauch, T., Steinbrecher, A., Brawanski, A., Proescholdt, M., Schlaier, J., Buchroithner, J., et al. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0053 · Cited by 215
Self-citationTargeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195
Self-citationInhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2
Kuppner, M. C., Hamou, M.-F., Sawamura, Y., Bodmer, S., & de Tribolet, N. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.2.0211 · Cited by 150
Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dörries, R., Schlingensiepen, K.-H., & Brysch, W. (1993) · Journal of Neurosurgery · doi:10.3171/jns.1993.78.6.0944 · Cited by 146
Self-citationOptimising the design of phase II oncology trials: The importance of randomisation
Ratain, M. J., & Sargent, D. J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.029 · Cited by 139
Kuppner, M. C., Hamou, M., Bodmer, S., Fontana, A., & De Tribolet, N. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420416 · Cited by 133
Future of Convection-Enhanced Delivery in the Treatment of Brain Tumors
Bidros, D. S., Liu, J. K., & Vogelbaum, M. A. (2009) · Future Oncology · doi:10.2217/fon.09.135 · Cited by 110
Maxwell, M., Galanopoulos, T., Neville-Golden, J., & Antoniades, H. N. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.76.5.0799 · Cited by 107
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
Wu, W., Lamborn, K. R., Buckner, J. C., Novotny, P. J., Chang, S. M., O'Fallon, J. R., Jaeckle, K. A., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop019 · Cited by 101
Temozolomide in the treatment of recurrent malignant glioma
Chang, S. M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., & Prados, M. D. (2004) · Cancer · doi:10.1002/cncr.11949 · Cited by 90
Jachimczak, P., Hessdörfer, B., Fabel-Schulte, K., Wismeth, C., Brysch, W., Schlingensiepen, K.-H., Bauer, A., Blesch, A., & Bogdahn, U. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960126)65:3<332::aid-ijc10>3.0.co;2-c · Cited by 84
Self-citationSchlingensiepen, R., Goldbrunner, M., Szyrach, M. N. I., Stauder, G., Jachimczak, P., Bogdahn, U., Schulmeyer, F., Hau, P., & Schlingensiepen, K.-H. (2005) · Oligonucleotides · doi:10.1089/oli.2005.15.94 · Cited by 69
Self-citationYang, X., Jin, G., Nakao, Y., Rahimtula, M., Pater, M. M., & Pater, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960126)65:3<275::aid-ijc1>3.0.co;2-x · Cited by 50
Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme
Hall, W. A., & Vallera, D. A. (2006) · Neurosurgical Focus · doi:10.3171/foc.2006.20.4.15 · Cited by 46
Expression of TGF‐β2 in Human Glioblastoma: A Role in Resistance to Immune Rejection?
Fontana, A., Bodmer, S., Frei, K., Malipiero, U., & Siepl, C. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514061.ch15 · Cited by 36
Trial design for evaluation of novel targeted therapies
Farley, J. H., & Rose, P. G. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.046 · Cited by 15
Advances and Technical Standards in Neurosurgery, Volume 19
Conley, F. K. (1993) · Neurosurgery · doi:10.1097/00006123-199311000-00032 · Cited by 9
Research works printed but not linked: 1
- Fontana A Bodmer S Frei K Malipiero U Siepl C Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection? Ciba Found Symp. 1991 157 232 241 1649035
Cited by
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Metadata
- Authors
- Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., Poverennova, I., Zaaroor, M., Jachimczak, P., Ludwig, S., Schmaus, S., Heinrichs, H., Schlingensiepen, K. H., & the Trabedersen Glioma Study Group
- Affiliations
- University of Regensburg (DE)
- Sanjay Gandhi Post Graduate Institute of Medical Sciences (IN)
- Corresponding author
- Bogdahn, U.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10-27
- Volume
- 13
- Issue
- 1
- Pages
- 132-142
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC3018908
- OpenAlex
- W2116583846
- Cited by
- 433
- References
- 34
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 28 · 2023: 29 · 2022: 28 · 2021: 21 · 2020: 33 · 2019: 24 · 2018: 24 · 2017: 31 · 2016: 22 · 2015: 39 · 2014: 34 · 2013: 31 · 2012: 33
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neuro-Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- high-grade glioma, anaplastic astrocytoma, temozolomide, procarbazine, lomustine, and vincristine, tumor control rate, survival, dose-finding, adverse events
- MeSH terms
- Adult, Antineoplastic Agents, Brain Neoplasms, Female, Glioblastoma, Humans, International Agencies, Male, Middle Aged, Neoplasm Recurrence, Local, Oligodeoxyribonucleotides, Thionucleotides, Survival Rate, Treatment Outcome, Transforming Growth Factor beta2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.